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Abstract
Social determinants of health (SDoH) can impact the vulnerable pulmonary
arterial hypertension (PAH) population, especially during the COVID‐19
pandemic. Providers' understanding of SDoH at the point of care and their
impact is unknown. We conducted semi‐structured virtual interviews with US
clinicians at 17 pulmonary hypertension (PH) centers and one patient
advocate from the Pulmonary Hypertension Association. We sought participants' perspective on SDoH in PAH and their impact. Transcripts were
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developed and analyzed for key themes to assess potential policy implications.
Participants served a large PAH population and demonstrated high awareness
of SDoH and its impact on treatment and outcomes. They reported that
patients' SDoH, including socioeconomic status, health insurance, access to
health care, education levels, health literacy, employment status, and
insecurities associated with housing, food, transportation, and family support,
impacted health and well‐being. COVID‐19‐related social isolation, mental
health, and substance abuse contributed to significant inequities in care
provision and outcomes. While telemedicine helped clinicians manage
patients remotely during the pandemic, there was a concern for patients with
limited access to this medium. Participants reported no formal screening for
SDoH at the point of care. With the recognition and the desire to act upon
health inequities associated with SDoH, participants felt that it was vital for
their centers to have a dedicated PH social worker and support staff to
optimize care and outcomes. An approach that integrates SDoH in PAH care
management, streamlined through institutional policy, could address health
disparities leading to improved healthcare access, outcomes, and quality
of care.
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I N T R O D U C TI O N
Healthy People 2030, a national initiative of the US
Department of Health and Human Services, defines
social determinants of health (SDoH) as “the conditions
in the environment where people are born, learn, work,
play, worship, and age that affect a wide range of health,
functioning, and quality of life outcomes and risks.”1
Traditionally the United States has focused on its
healthcare system to improve health and health outcomes. However, there continues to be greater
recognition that the nonmedical factors, including an
individual's socioeconomic status, housing, education,
neighborhood, employment, social support, access to
nutritious food, safe living environment, and access to
healthcare as drivers of poor health and health outcomes.2 Evidence from an analysis conducted over
30 years and reported in the year 2000 attributed SDoH
to US adult deaths as follows; 245,000 due to low
education, 176,000 due to racial segregation, 162,000 due
to low social support, 133,000 due to individual‐level
poverty, and 119,000 due to income inequality.3
Provider knowledge of SDoH is vital to address
individual social needs through community‐level referrals for improved prognosis and quality of life in the
context of socioeconomics and environment.4 Research
also suggests that proper interventions to address SDoH
can result in positive outcomes.5 The awareness and
understanding of SDoH are evolving, focusing on
chronic conditions such as hypertension and diabetes
affecting large populations.6 However, smaller groups
of people impacted by rare diseases have not been the
focus of SDoH research despite a potentially similar
devastating effect at an individual, family, community,
and societal level.
Pulmonary arterial hypertension (PAH) is a rare and
progressive disease that involves increased pulmonary
vascular resistance, right ventricular pressure overload,
right heart dysfunction, right heart failure, and premature death.7 Despite the overall poor prognosis, PAH
patients experience a significant delay in diagnosis with
an average time from symptom onset to diagnosis of
about 3 years.8 While clinical, diagnostic, and therapeutic
advances have been made in the last few decades,
research efforts and evidence to understand the impact of
SDoH on PAH patients remain sparse.9–12 The American
Thoracic Society, in its 2017 official statement, identified
the need for providers to understand the impact of social
and environmental conditions on potential poor outcomes in PAH patients.13 A large number of PAH
patients in the US receive care from pulmonologists and
cardiologists in pulmonary hypertension centers (PHC)
that may be accredited or nonaccredited by the
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Pulmonary Hypertension Association (PHA).14 Awareness and knowledge of SDoH among the PH providers at
these specialized centers and their ability to intervene to
improve patient health outcomes is unknown. We aimed
to study clinician awareness of SDoH in their PAH
patients, current point‐of‐care practices, and potential
implications for care management and health policy.

ME T H OD S
We conducted 30‐min semistructured virtual interviews15 with a convenience sample of clinicians actively
engaged in treating PAH patients at US centers. In
addition, one patient advocate from PHA was interviewed to represent the patient perspective. We developed an interview guide using open‐ended questions and
probes based on the Healthy People 2030 SDoH
framework, including queries about healthcare access,
education, employment, neighborhood, social, and community factors that may impact the PAH patients.1 A test
interview with one PH clinician from Pulmonary
Hypertension Comprehensive Care Center (PHCCC)
was conducted to ensure relevance and overall flow.
Invitations to participate in the study were sent via email
using contact information sourced from institutional and
PHA websites. A brief preinterview questionnaire was
emailed seeking information on participants' demographics and practice characteristics that included an
estimated PAH patient population profile.
Virtual interviews with interested participants were
scheduled and conducted by a trained postgraduate
student using Microsoft Teams. Interviews were recorded
to develop transcripts with participant permission. After
the interview, a brief 10‐item SDoH screening tool,
derived from the Health Leads Social Needs Screening
Toolkit that was successfully implemented previously in
patient care, was shared via email to seek participant
feedback on its relevance and potential use in PAH
routine clinical practice.16–19 As a thank you, participants
were offered a $50 Amazon e‐gift card or a donation to a
charity of their choice.
After completing the interviews', deidentified transcripts were developed. We conducted qualitative analysis by reviewing and grouping frequently occurring
themes of SDoH in PAH patients. Relevant quotations
from participant interviews were highlighted to reinforce
the key themes. Participant demographics and practice
characteristics were entered in a Microsoft Excel
spreadsheet and analyzed to develop aggregate summaries for each variable. We summarized feedback on the
SDoH screening tool and discussed health policy
implications.
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Study methods

Figure 1 highlights an overview of the study flow and
procedures, including the study periods. This study
involved information‐gathering interviews, questions
focused on information and opinions about processes,
services, or policies, and did not gather personal
information about living individuals. Our University's
Office of Human Research deemed it does not require
Institutional Review Board submission.

RESU LTS
Participant, practice, and PAH patient
population characteristics
The study included 17 clinicians from the United States
(Table 1), 15 (88%) from PHA accredited PHCCCs, two
(12%) from nonaccredited PH centers, and one patient
advocate from PHA. The 17 clinicians included 13
pulmonologists and four cardiologists with a group
average of 19 years of experience in treating PH patients.
The participants reported caring for an average of 321
PAH patients across centers with an average age of
52 years, predominantly women (73%) and of Caucasian
(61%) race (Table 1). Patients were either unemployed
(34%) or retired (23%), and a little over half were
estimated to have public health insurance (51%) coverage
such as Medicaid and Medicare. Patients had high

severity of illness as assessed by World Health Organization Functional Class (WHO FC) and required combination therapy with 2 or 3 medications (Table 1).

Participant awareness of SDoH
When asked what the term SDoH meant to them, study
participants demonstrated a high awareness describing
the interconnectivity, including an individual's health,
healthcare access, socioeconomic status, and environmental factors (Figure 2a). In one participant's words,
“it's an individual's condition or his or her environment.”
This participant described SDoH as “where you're born,
your education, your access to health care, your
economic situation, your social constructs, whether it's
your interpersonal relationships, your religious organizations might be part of, and how that impacts your health
and quality of life.” Another participant opined that “I
think the social determinants of health have a lot to do
with our identity.”

SDoH impact on PAH populations
Participants shared that patients' clinical care is impacted
by several nonclinical factors, including health insurance
coverage, transportation issues, employment, unstable
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PH clinician and practice characteristics

TABLE 1

N = 17

PH clinician characteristics

N = 17

PAH therapy, mean % (range)

Pulmonologist

13 (76%)

Cardiologist

4 (24%)

PH clinician treatment experience, mean
years (range)

19.3 (6–37)

PH clinician practice setting, n (%)
PHA accredited PHCCC

15 (88%)

Nonaccredited PHC

2 (12%)

PHC geographic location, n (%)
Northeast

6 (35%)

West

5 (29%)

Midwest

4 (24%)

Southwest

1 (6%)

Southeast
PH clinician practice characteristics

(Continued)

PH clinician practice characteristicsa

PH clinician specialty, n (%)

ET AL.

1 (6%)
a

Number of active PAH patients, mean
(range)

N = 17
321 (125–600)

Patient age, mean years (range)

52 (35–65)

Time to diagnosis, mean years (range)

1.5 (1–3)

Gender, mean % (range)
Female

73% (60%–88%)

Male

27% (12%–40%)

Race/Ethnicity, mean % (range)
Caucasian

61% (30%–90%)

African American

22% (2%–50%)

Hispanic

12% (0%–40%)

Asian

5% (0%–15%)

Employment status, mean % (range)
Employed

43% (20%–90%)

Unemployed

34% (10%–60%)

Retired

23% (5%–90%)

Monotherapy

11% (5%–48%)

Double therapy

52% (25%–85%)

Triple therapy

37% (10%–70%)

Abbreviations: FC, functional class; PAH, Pulmonary Arterial Hypertension;
PH, Pulmonary Hypertension; PHA, Pulmonary Hypertension Association;
PHC, Pulmonary Hypertension Center; PHCCC, Pulmonary Hypertension
Comprehensive Care Center; WHO, World Health Organization.
a

Clinician practice characteristics are based on subjective information
provided by the participants.

housing, mental health, food insecurity, education levels,
and health literacy (Figure 2b). One participant said, “I
think these social determinants pervade everything we
do and every aspect of the patients from the lead time to
get diagnosed because it may put off symptoms because
they don't have insurance and don't want to pay to get
testing done. [SDoH is] in the background from well
before we see the patient, and it continues throughout
the entire patient experience.” The importance of living
conditions and social support was expressed by another
participant, “one of the important things is social
support, how much support they have, especially if we
are trying to talk about a complex regimen of therapy. If
you need IV, SubQ [PAH therapy], you should have good
social support. [For] one of my patients, when the
specialty nurse went to the home to do teaching, it wasn't
in the best hygienic condition that you would be
comfortable having someone using parenteral therapy.
Social support, living situation, and things like that
would be very important.”
We describe the study participants' perspectives and
experiences about the impact of specific SDoH on PAH
patients.

Employment status and disability

Health insurance status, mean % (range)
Public

51% (30%–90%)

Private

42% (5%–70%)

Uninsured

7% (0%–30%)

WHO functional class, mean %, (range)
FCI

7% (0%–25%)

FCII

45% (30%–65%)

FCIII

40% (25%–75%)

FCIV

8% (2%–30%)

Participants said patients' employment status and stability impact several aspects of their lives, including the
economic situation, affordability, and access to food,
housing, and transportation (Figure 3a). One participant
noted the impact of employment on patients from
multiple viewpoints; job directly influences their health
insurance, coverage and access to care, and medication
type. Work gives a sense of individual selfworth, keeps
them active, and helps them manage their health. While
dealing with the progressive nature of the disease, the
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(a)

FIGURE 2

(b)

Social determinants of health awareness and impact

(a)

FIGURE 3

(b)

Employment and housing
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type of employment—whether it involves sedentary work
or requires physical activity, working hours, ability to
take time off to attend to medical appointments, and
other elements, may induce different levels of stress and
anxiety while impacting health outcomes in the absence
of appropriate accommodations.
Participants estimated that a significant number of
their patients (35%–40%) were on disability. These
included young people in their 20 and 30 s who barely
worked and retirees who had worked all their lives. It
was noted that PAH patients experience difficulties
seeking and qualifying for disability benefits from social
security administration for their pulmonary hypertension, even when they are genuinely disabled. The
laws and rules by which disability is determined are not
the friendliest for PAH patients. In one participant's
words, “[PAH patients] often have to file, get denied,
seek a lawyer and appeal, and that costs, takes time and
money. And again, these are the patients who're not
working, and they don't have a nest egg, and so they're at
the mercy of the system. They sometimes struggle even to
get that disability, even when the health care community
and I perfectly are aligned, in thinking that this is a
disabled person, they can't work.” This participant
described the vulnerability of PAH patients in seeking
disability as intricately linked also to several other social
and economic factors, “I think those that have means to
the transportation and the finances and the education if
you will are more likely to be successful and those living
in their car who don't know how to manage their daily
lives, to begin with, are less likely to be assertive enough
to carry them down that pathway. Yeah, it's right, the
disadvantaged are further disadvantaged because of their
disadvantage.”

Housing insecurity
Participants recognized housing insecurity for PAH
patients. It can present in several ways, including not
having access to basic housing and housing with
interrupted utilities, including electricity, gas, and water
(Figure 3b). Air quality in the house, supported by
appropriately designed ventilation, heating, and cooling,
was necessary. The need for electricity to operate oxygen
and medication infusion pumps and instances where
power was cut off were cited as having a detrimental
effect on outcomes. Most patients do not have generators
as backup or the means to afford one. The housing
location, that is, those living in distressed neighborhoods
and patients impacted by domestic violence or violence
outside the home, caused patients' anxiety, depression,
and decrements in their quality of life, ultimately
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worsening outcomes related to PAH. Stable housing
and having an address to facilitate shipping of PAH
specialty medications also impact treatment choice and
health outcomes.

Food insecurity
Participants reported that there were groups of PAH
patients who had to choose between their food and
medications. It was directly associated with the economic
stressors of housing. Clinicians mentioned considering a
complex web of social factors that directly impacted
their clinical decision‐making and care management
for their patients. In one participant's words, “those
[healthy meals] are not the meals that are being
prepared, again, if you are working three jobs or have
very poor income, or, if you live in a food desert or not
even going to be able to access those, and so that's the
problem, or, you don't have time to prepare them, or
you don't have the resources to prepare them, right?
You don't have a working stove or a gas line, or even in
more extreme cases, you don't have electricity. So those
are all circumstances where you're relying on either,
and if you, unfortunately, suffer from homelessness
and you're into things such as soup kitchens, which by
definition have a lot of salts associated with them. So,
then this poor nutrition is associated with an increased
risk of hospitalization. It's associated with decreased
efficacy of treatment, and it is associated with
premature mortality.”

Transportation insecurity
The participants referred to the lack or limited access to
transportation for PAH patients as a major issue with
10%–15% impacted severely based on their social factors,
including where they live, income levels, and family
support (Figure 4). There are a limited number of PH
expert centers and are primarily located in urban areas
requiring patients to travel long distances. Access to
transportation impacts therapy choices. For example,
complex therapy requires frequent follow‐ups and in‐
person visits, and this can be challenging if the patient
does not have access or means to reliable transportation.
Lack or limited access to transportation and telehealth
tools may delay care and result in the utilization of
urgent care centers, emergency rooms, and hospitalizations for assessment and management. For patients, this
results in poor health outcomes and higher healthcare
resource utilization and ultimately increased costs for the
health system.

|
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Transportation insecurity

Education and health literacy
Participants indicated that PAH patient outcomes were
related to their education levels, contributing to their
employability, income levels, and access to health
insurance. It was noted that those without higher
education face more significant challenges in accessing
medical care impacting health outcomes negatively. PAH
therapies involve complex treatment regimens. Some
medications are delivered via automated pumps that
require a basic understanding of device operations,
alarms, changing medication titration settings, and
troubleshooting in case of malfunction. Intellectual
capacity and social support were noted as requirements
for lung transplantation; when disadvantaged, they could
not access these last‐resort medical options. One participant shared, “I think both [level of education and disease
education] is important. This is a disease that requires
some degree of understanding and is difficult to explain.
You know, it affects the heart, affects the lungs. You may
have a systemic disease that affects a lot of different
things in addition to the heart and the lungs. And so, you
know, how does this medicine work. So, there is a basic
level of understanding required to successfully manage
this disease.”
In addition to education levels, health literacy and an
individual's ability to understand health information to

make appropriate health decisions were necessary for
patients to manage their condition.

Language and cultural competency
Participants identified their patients' language, ethnic
and cultural backgrounds as important determinants,
and provider knowledge, understanding, and competencies directly impacted health outcomes. It was noted by
participants from locations where large populations of
various ethnicities, including Hispanics and Asians, were
present; that the care team needed to interact in patients'
native language due to cultural aspects impacting care.
Participants highlighted that language barriers and
cultural competency challenges might create disparities
in care and outcomes for this population.

Racial and ethnic disparities
Most participants did not directly identify race‐related or
ethnic disparities in PAH patient diagnosis, treatment,
and prognosis. However, recognized socioeconomic
status, health literacy, employment, and income levels,
irrespective of race, were reported to have similar
barriers to accessing care. In one participant's words,
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“I'm gonna say that I'm not sure that the relevant factor
is race as much as socioeconomic status, health literacy,
and you know, people that we would describe as
economically disadvantaged no matter what race they
have, had the same barriers to access to health care to
early diagnosis. While if you're upper‐middle class, you
may see your physician for [any ailment] you have, and
[PAH] diagnosis may occur earlier. The likelihood of
referral from a community setting to an academic
medical center with an experienced PAH center may be
more likely, so I think it really depends on socioeconomic status, perhaps more than race.”
While this was not the predominant view, another
participant pointed to the potential underreporting of
PAH in ethnicities of minorities such as African
Americans, Hispanics, and Asians, likely indicating the
impact of SDoH, “Yeah, pulmonary hypertension does
not seem to be a disease that is affected by ethnicity, and
so there are equal proportions likely in each of those
ethnic groups. This is where social determinants of
health become very important because many people with
ethnicities other than Caucasians are underrepresented
in the majority of our registries. So, though it's clear that
there is no genetic predisposition based on race, we know
less about how this disease affects others, particularly in
African descent, Hispanic descent, and so on, at least in
the United States.”

FIGURE 5

Mental health

ET AL.

Mental health and substance use disorders
Mental health was one of the more significant problems
reported by study participants impacting their PAH
patient outcomes (Figure 5). Many patients suffer from
anxiety and depression as PAH is often a rapidly
progressive and fatal disease. Mental health directly
impacts their physical health. In one participant's words,
“the psychological milieu of the patient really affects the
disease course.”
A quarter of the participants at PHCCCs with high
substance use disorder prevalence reported it as a
significant issue and was interrelated to several SDoH
in their patients. Illicit substances such as methamphetamine and cocaine are known to induce
PAH.20,21 The prognosis for these patients was better
when they could stop using these substances, and proper
treatment and mental health services were provided. One
participant said, “we see a significant number of patients
in our practice that have had some type of substance
abuse. I'd say maybe you know 10%–15% of our clinic,
and it can be a huge problem because especially if they
are still actively using because adherence and access to
care all those things [SDoH) are just magnified if they
have a substance abuse that you know is another blanket
that you layover, which directly impacts how we manage
patients.” The SDoH associated with drug abuse was
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more complicated, including the social stigma associated
with diagnosis, treatment, lack of pharmacotherapy, and
inadequate or lack of treatment centers. These patients
were known to be vulnerable and experiencing loss of
employment, homelessness, food insecurity, domestic
abuse, crime, and violence, often interfacing with the
criminal justice system, posing significant PAH diagnosis
and management challenges. The lack of access or
resources for referral to the drug addiction centers and
follow‐through at the point of PAH care makes it further
complicated. One participant had a dedicated PH social
worker and case manager to provide referral services to
addiction centers, but expressed doubt in efficiency at a
system level, suggesting that integrating mental health
services in PH care provision is vital for continuity of care
focused on improving health outcomes.

imaging, and the need for extra‐precautions and measures
between staff and patients (Figure 6a). Participants also
reported COVID‐19 impacted transport lines, resulting in
shipping delays and sometimes affecting the delivery of life‐
saving PAH medications. PAH patients with jobs that
required physical presence were not able to attend to their
jobs due to their underlying condition, which resulted in
further economic and mental burdens leading to more
stress and anxiety. While participants reported the benefits
of telemedicine to overcome some COVID‐19 restrictions,
they also noted some challenges associated with this tool in
some patients who did not have access to optimal devices
and the Internet to provide quality audio–video streaming.
Furthermore, the knowledge and ability to operate
smart devices were reported to complicate the situation.
This can be illustrated well in one of the participants'
words, “some people can't do [quality telemedicine] visits
because they don't have good Internet, or they don't have
smartphones. So, where you live affects your ability to
have good Internet, which affects how we're able to care
for somebody in terms of communicating electronically.”

COVID‐19 pandemic and SDoH
Participants reported that COVID‐19 impacted access to
care. Many PAH patients were unable or unwilling to be
hospitalized or to have an in‐person clinic visit due to
concern that they might contract COVID‐19 or due to
reductions in healthcare services resulting in capacity issues
and inability to complete necessary testing such as right
heart catheterizations, echocardiograms, 6‐min walk tests,
pulmonary function tests, ventilation‐perfusion scans,

(a)

FIGURE 6
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SDoH screening and implementation
Participants reported that SDoH was neither screened
nor routinely collected at the centers (Figure 6b). A
quarter of participants said they collected health‐related

(b)

COVID‐19 and social determinants of health screening

10 of 14
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quality of life using standard patient‐reported outcomes
measures, including impact on psychosocial issues.
However, these instruments were not designed to
capture their social needs, that is, SDoH. Participants
reported relying upon their interactions with patients,
supplemented by what their nurses or administrative
assistants inform them. One participant's words, “I think
[screening for SDOH] is a bit challenging, but we rely
upon our own interactions with our patients and what
our nurses tell us, or our administrative assistants tell us.
We review all our patients in the clinic who are attending
the clinic the week before. So, we have a group meeting,
and issues like this may come up regarding whether it's
health care, literacy or economic issues, or other things
like that might influence a patient's care, but I don't
think we're specifically trained and being sensitive
enough to pick up on all those factors. It's really the
most gross examples that are being brought to our
attention, you know, some.” Another participant said,
“we don't have a screening tool for [SDoH]. It's usually a
case‐by‐case exploration and trying to feel the social
situation for especially new patients and getting to know
changes that happened to current patients. Still, we don't
have, for example, an official screening tool that patients
answer, and you can pick up some of those situations to
help identify people at risk.”
Participants responded favorably to the idea of
implementing an easy‐to‐use, PH population relevant
SDoH screener, “yeah. I think you need to have a
dedicated questionnaire that will include [social] factors.” Participants expressed interest in screening for
SDOH of their PAH patients and acknowledged it was
not on top of their list due to a lack of a tool and lack of
resources to follow through on the social issues. The
absence of a dedicated PH social worker was a significant
barrier to bridging their patients' social needs through
community referrals. The institutional barriers, according to one participant, were “social work is not one of
those things that pay its own bills, and so when hospitals
cut costs, social work and palliative work, are the ones
that are cut first and so a lot of our patients don't have
access to the social and palliative networks that they
should be given access to.” Also, participants responded
favorably to the relevance and potential use of the 10‐
item SDoH questionnaire with the PH population at the
point of care. One participant said, “I can't think of any
other concept/field that should be covered in this sample
tool.” However, they raised relevant practical issues such
as “I am curious how you propose to include this in the
EMR, namely wherein the patient encounter and how
often this would be applied. As you know, these
determinants change over time, but there tends to be
survey fatigue both by the patient and the provider.
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Importantly, interpretation and intervention need to be
specified and pathways defined to address issues identified; otherwise, the clinical utility is limited.”

D I S C U S S IO N
Our study is the first to bring an understanding of
clinician awareness and knowledge of SDoH in the PAH
patient population. Experienced clinicians from PHCCCs
across the US were highly aware of SDoH and shared
how their patients' socioeconomic factors impacted their
clinical care. Our study findings provide PAH clinicians'
views that support emerging evidence indicating that
PAH patients with negative SDoH correlated with poor
health outcomes.9–12 Talwar et al. identified that lower
income levels in PAH patients were associated with the
worse disease as measured by higher WHO‐FC at initial
evaluation.9 A study focused on portopulmonary hypertension patients enrolled in the Pulmonary Arterial
Hypertension Registry (PHAR) revealed that portopulmonary hypertension patients had a lower socioeconomic status when compared to idiopathic PAH
patients with increased healthcare utilization.11 In the
same study, a lower education level was associated with
more emergency department visits highlighting the
impact of health disparities in this group of patients.11
Another recent study reported that PAH patients of
Hispanic ethnicity had impaired healthcare access, lower
education levels, income levels, and higher levels of
emergency room visits and hospitalizations than their
non‐Hispanic White counterparts despite having similar
disease severity.12 In this study, while the unadjusted
analysis of transplant‐free survival suggested a better
survival in Hispanic PAH patients, this was no longer the
case after adjustment for covariates that included SDoH,
which highlights the importance of considering SDoH in
PAH outcome studies.12 While our study sought a view
about disparities of care amongst races and ethnicities,
we did not directly identify race‐related disparities in
patient diagnosis, treatment, and prognosis. However,
participants recognized that poor socioeconomics disadvantaged patients irrespective of their race. There were
mixed findings from recent studies and may call for
further investigation.12,22–25
Our study findings should be helpful in informing a
future PH practice model that includes screening for
social needs domains (housing instability, utility strain,
food insecurity, transportation, financial resources strain,
and exposure to violence, childcare, and behavioral and
mental health) using the brief 10‐item SDoH questionnaire upon patient's initial visit and at appropriate
subsequent visits that can range every 6 or 12 months,
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with due consideration for patient survey fatigue and
provider burden. These data, when integrated to the
patient's medical record, should present the clinician
with a holistic view of their patient's clinical and
nonclinical challenges and help proactively manage with
the aid of a dedicated social worker and support staff to
address barriers including transportation, unstable housing,
and food insecurity through community referrals and
partnerships that were previously successful with a positive
patient and system‐wide impact.26,27 We recognize that it
may not be feasible to immediately implement a quick
SDoH screening and execution plan as it involves buy‐in
from several institutional stakeholders, including the
PHCCC leadership, interdisciplinary PH care team, and
institutional administrators, with potentially conflicting
priorities. For instance, the clinical team focuses on
improving care for their patients, while the institutional
administrators focus on financial and return on investment
decisions. Initiatives such as the protocol for responding to
and assessing patients' assets, risks, and experiences
(PRAPARE) can be helpful for PHCCCs in implementing
SDoH in their routine practice to improve population
health outcomes.27 To this effect, we present an integrated
SDoH PH practice model for potential implementation at
the PH centers of excellence (Figure 7).
Currently, PHA accreditation requirements include
social work in the program staff and support services
category, needing resources or an established referral

FIGURE 7
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pattern.14 Our study findings indicate clinicians at
PHCCCs are seeking dedicated social support. We believe
PHA and other patient organizations have a significant
role to play. For example, PHA may consider specifying
social workers' full‐time equivalent proportion in the
accreditation criteria or requiring pilot quality improvement initiatives aligned with national SDoH‐focused
quality improvement initiatives.26 This should help
improve the uptake of SDoH screening, measurement,
analysis, and point‐of‐care application to clinical
decision‐making focusing on patient outcomes.
Though we sought one patient advocate's perspective, our study heavily focused on clinicians' perspectives. Hence, it is crucial to explore PAH patients'
perspectives on SDoH to advance patient‐centered
care. A recent survey indicated that nearly half of
Americans (46%) were unaware of social drivers of
health. Once defined as SDoH, 60% of Americans
agreed that their local community faces at least some
health issues related to SDoH.28 Educational efforts
from patient associations like PHA should include
SDoH and their potential impact on individuals' health
and life outcomes. These can be modules made
available through PHA providers and patient education material. Additionally, the educational material
on SDoH can be built into the patient peer support
programs to bring awareness and share helpful
resources for PAH patients and their families.

Integrated social determinants of health PH practice model
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The tsunami created by the COVID‐19 pandemic
greatly impacted PAH practice and patients. Although
telemedicine mitigated particular COVID‐19 challenges,
some patients were disproportionately disadvantaged
because of the inequities associated with Internet access,
devices, and lack of technology savviness. This is
particularly important as digital literacy and internet
connectivity has been the “super social determinant of
health” as they are intricately linked to all other SDoH.29
It must be observed in the context of the role of digital
outreach to impacted patient communities where the
majority of modern patient advocacy organizations such
as PHA's outreach, educational and advocacy efforts are
Internet‐based. It behooves the PH community to pay
close attention to the SDoH of internet inequity.
Our study findings should be considered with some
limitations. We sought clinician subjective inputs on
their practice characteristics; though consistent with the
study methodology, it should be noted that these are
nonvalidated qualitative estimates based on participant
awareness and experience. The results may reflect
clinicians at PHCCCs and may not be generalizable to
clinicians at nonaccredited PH centers and clinics. There
also may be a selfselection bias with only knowledgeable
and interested providers accepting to participate in the
study. Hence, they may have shown greater awareness of
SDoH in their patients. Also, it is possible participants
could have prepared for the interview topic, and as such
there was high awareness. The clinician's perspective on
SDoH may not fully reflect PAH patients' awareness,
understanding, experience, and the extent of the SDoH
on their health. Though we sought the perspective of a
patient advocate from PHA, it identifies an opportunity
to study SDoH impact on PAH patients' health and living
experience. While our study used a single coder, we
ensured careful review and discussions to validate the
consistency in the themes and to minimize potential
interpretation bias of participant perspectives.
PH clinicians at PHCCCs were highly aware of the
inequities in healthcare for PAH patients, an already
vulnerable population, further negatively impacted due
to their social and economic disadvantages. Health policy
efforts at an institutional and national level must focus
on screening and follow‐up aided by referrals through
community partnerships. Future research should include
SDoH data integration to patient registries to methodically study the impact of SDoH on patient outcomes
across PHCCCs.30 The SDoH evidence obtained from
such initiatives should be helpful for inclusion in PH
risk‐scoring algorithms to produce a holistic risk score
inclusive of clinical and nonclinical data aiding in risk
stratification to predict patients with the most significant
health needs.31 SDoH should be integral to holistic care,
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as we learned from our study participants that one size
does not fit all, and PH care must be customized
depending on patient needs. Efforts to consider the
PAH patient's SDoH are also consistent with efforts to
integrate patient voice for patient‐centered care.32,33
Health policy initiatives to inform SDoH integration to
routine PAH care management is paramount to addressing disparities and improving equality in healthcare
access, outcomes, and quality of care.
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